Cargando…
Drug discovery of sclerostin inhibitors
Sclerostin, a protein secreted from osteocytes, negatively regulates the WNT signaling pathway by binding to the LRP5/6 co-receptors and further inhibits bone formation and promotes bone resorption. Sclerostin contributes to musculoskeletal system-related diseases, making it a promising therapeutic...
Autores principales: | Yu, Sifan, Li, Dijie, Zhang, Ning, Ni, Shuaijian, Sun, Meiheng, Wang, Luyao, Xiao, Huan, Liu, Dingdong, Liu, Jin, Yu, Yuanyuan, Zhang, Zongkang, Yeung, Samuel Tin Yui, Zhang, Shu, Lu, Aiping, Zhang, Zhenlin, Zhang, Baoting, Zhang, Ge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136615/ https://www.ncbi.nlm.nih.gov/pubmed/35646527 http://dx.doi.org/10.1016/j.apsb.2022.01.012 |
Ejemplares similares
-
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
por: Yu, Yuanyuan, et al.
Publicado: (2022) -
Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice
por: Wang, Luyao, et al.
Publicado: (2022) -
The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research
por: Sun, Meiheng, et al.
Publicado: (2021) -
A Loop‐Based and AGO‐Incorporated Virtual Screening Model Targeting AGO‐Mediated miRNA–mRNA Interactions for Drug Discovery to Rescue Bone Phenotype in Genetically Modified Mice
por: Zhuo, Zhenjian, et al.
Publicado: (2020) -
Drug Discovery of DKK1 Inhibitors
por: Jiang, Hewen, et al.
Publicado: (2022)